RG
SCLN

Renaissance Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Renaissance Group’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-41,953
Closed -$208K – 211
2013
Q2 		$208K Buy
+41,953
New +$200K 0.01% 171

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Group's SCLN Position: Q3 2013 in Review

Renaissance Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2013, closing a stake of 41,953 shares — an estimated $208K sold.

Renaissance Group first reported a position in SCLN in Q2 2013 and held it in 1 quarter. The position peaked at $208K in Q2 2013. 102 funds tracked by Wall St. Rank hold SCLN as of Q3 2013.

  • Renaissance Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • Renaissance Group sold 41,953 Sciclone Pharmaceuticals Inc shares in Q3 2013, an estimated $208K.
  • Renaissance Group first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • Renaissance Group's Sciclone Pharmaceuticals Inc position peaked at $208K in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2013.

Based on Renaissance Group's 13F filing for Q3 2013, filed 12 Nov 2013.